Untangling Sarepta’s gene therapy fallout and a growing trust deficit
The Top Line1 Aug 2025

Untangling Sarepta’s gene therapy fallout and a growing trust deficit

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple patient deaths.

In this week’s episode of "The Top Line," we explore Sarepta’s brief standoff with the FDA over Elevidys, a short-lived marketing pause, and the regulator’s surprise reversal on the treatment. Fierce Pharma’s Fraiser Kansteiner and Angus Liu sit down with Fierce Biotech’s Gabrielle Masson to recap the story and discuss the broader implications the Elevidys saga may have for gene therapy, the FDA and the pharmaceutical industry.

To learn more about the topics in this episode:

See omnystudio.com/listener for privacy information.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(100)

How we picked the Fierce 15

How we picked the Fierce 15

What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector.In this wee...

9 Okt 23min

Locking in on pharma’s consumerization trend

Locking in on pharma’s consumerization trend

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern-hair-loss biotech is eyeing opportunities in an evolving m...

2 Okt 18min

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and communications. In this episode of "The Top...

25 Sep 24min

Inside the growing world of biopharma prediction markets

Inside the growing world of biopharma prediction markets

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researche...

18 Sep 23min

Clinical trials reach a new automation inflection point (Sponsored)

Clinical trials reach a new automation inflection point (Sponsored)

Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation has improved individual process...

14 Sep 17min

The future of RAS inhibitors

The future of RAS inhibitors

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach...

11 Sep 29min

The people who stayed with the problem

The people who stayed with the problem

The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vacci...

4 Sep 25min

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most appropriate treatment. In...

2 Sep 13min

Populært innen Politikk og nyheter

giver-og-gjengen-vg
aftenpodden
forklart
stopp-verden
aftenpodden-usa
popradet
fotballpodden-2
det-store-bildet
dine-penger-pengeradet
rss-gukild-johaug
rss-espen-lee-usensurert
hanna-de-heldige
nokon-ma-ga
rss-penger-polser-og-politikk
rss-ness
aftenbla-bla
bt-dokumentar-2
frokostshowet-pa-p5
e24-podden
ta-dokumentar